FindMyKOL
Clinical trialNCT02319018CompletedPhase 1Interventional

Alisertib and Combination Chemotherapy in Treating Patients With Gastrointestinal Tumors

SponsorNational Cancer Institute (NCI)Enrollment14Malignant Digestive System Neoplasm
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This phase I trial studies the side effects and best dose of alisertib when given together with combination chemotherapy in treating patients with gastrointestinal tumors. Alisertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as fluorouracil, leucovorin calcium, oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving alisertib with more than one drug (combination chemotherapy) may be a better treatment for gastrointestinal tumors.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

5 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Smilow Cancer Center/yale-New Haven Hospital

    New Haven, Connecticut, United States

  • Yale University

    New Haven, Connecticut, United States

  • Johns Hopkins University/sidney Kimmel Cancer Center

    Baltimore, Maryland, United States

  • Wayne State University/karmanos Cancer Institute

    Detroit, Michigan, United States

  • Vanderbilt University/ingram Cancer Center

    Nashville, Tennessee, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

AlisertibFluorouracil →Leucovorin →Oxaliplatin →
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
27 Aug 2015
Primary completion
29 Sept 2018
Completion
29 Sept 2018
Last update posted
9 Oct 2018
Registered enrollment
14
Registry id
NCT02319018
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.